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Abstract 
Background 
How systemic inflammation-based prognostic scores such as the modified Glasgow 
Prognostic Score (mGPS) and neutrophil:lymphocyte ratio (NLR) differ across populations of 
patients with colorectal cancer (CRC) remains unknown.  The present study examined the 
mGPS and NLR in patients from United Kingdom (UK) and Japan.   
Methods 
Patients undergoing resection of TNM I-III CRC in two centres in the UK and Japan were 
included. Differences in clinicopathological characteristics and mGPS (0-CRP≤10mg/L, 1-
CRP>10mg/L, 2-CRP>10mg/L, albumin<35g/L) and NLR (≤5/>5) were examined. 
Results 
Patients from UK (n=581) were more likely to be female, high ASA and BMI, present as an 
emergency (all P<0.01) and have higher T stage compared to those from Japan (n=559).  
After controlling for differences in tumor and host characteristics, patients from Japan were 
less likely to be systemically inflamed (OR: mGPS: 0.37, 95%CI 0.27-0.50, P<0.001; NLR: 
0.53, 95%CI 0.35-0.79, P=0.002).  
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Conclusion 
Systemic inflammatory responses differ between populations with colorectal cancer.  Given 
their prognostic value, reporting of systemic inflammation-based scores should be 
incorporated into future studies reporting patient outcomes. 
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Summary: Although the systemic inflammatory response is recognised as a prognostic factor 
in patients with colorectal cancer, it is not clear how these may differ between distinct 
geographical populations. The present study examines differences in the prevalence of 
elevated systemic inflammatory responses (modified Glasgow Prognostic Score and 
neutrophil:lymphocyte ratio) between two populations undergoing resection of colorectal 
cancer in the United Kingdom and Japan. 
Keywords: colorectal cancer; systemic inflammation; systemic inflammatory response  
5 
 5 
 Introduction 
Colorectal cancer is the third most commonly diagnosed cancer worldwide (1).  Although 
prognosis of patients with early stage disease may be excellent, ultimately 40% of patients 
across all disease stages die from their disease within five years (2).  Staging and additional 
treatment is primarily based upon assessment of pathological characteristics of the tumor, 
with the presence of regional lymph node metastases (TNM stage III) an indication for 
adjuvant chemotherapy.  Similarly, other pathological characteristics, such as venous 
invasion, may also identify patients with high-risk, node negative disease likely to benefit 
from chemotherapy (3). 
In addition to tumor-based characteristics, the host systemic inflammatory response is now 
recognised as an important determinant of disease progression (4).  Assessment of the host 
systemic inflammatory response, utilising routinely measured circulating biomarkers, such as 
acute phase proteins and components of the differential white cell count (5), has prognostic 
value across a number of cancers, and several inflammation-based prognostic scores have 
been proposed to this effect. 
One such score is the modified Glasgow Prognostic Score (mGPS), a cumulative score based 
on pre-operative serum concentrations of the routinely measured acute phase proteins C-
reactive protein (CRP) and albumin (6).  In patients with colorectal cancer, the mGPS has 
complimentary prognostic value to routine TNM-based staging of patients undergoing 
resection of stage I-III disease, and may potentially select for patients with stage III colon 
cancer less likely to derive benefit from adjuvant chemotherapy (7).  Therefore, it is of 
interest that the mGPS has been validated internationally in patients with colorectal cancer (6, 
8).  Similarly, the systemic inflammation-based neutrophil: lymphocyte ratio (NLR), has been 
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shown to hold independent prognostic value in patients with colorectal cancer internationally 
(8-10).  Given their routine availability, objectivity and potential role as both prognostic and 
predictive markers, such inflammation-based scores would be a useful adjunct to the routine 
staging of patients with colorectal cancer.   
However, although individual studies and pooled analyses have confirmed the prognostic 
value of both the mGPS and NLR in patients from distinct ethnic populations (7-13), it is 
recognised that ethnicity itself may confound the presence of a systemic inflammatory 
response.  For example, population studies have found individuals of Black and South Asian 
origin have higher CRP concentrations than those of Caucasian descent (14-16), whereas 
individuals of East Asian heritage have consistently been reported to having significantly 
lower concentrations (17-19).  Although studied in healthy subjects and cardiovascular 
disease screening programmes, it is not clear whether the presence of a cancer-associated 
systemic inflammatory response similarly differs with ethnicity.  Given the prognostic 
implications, it would be of interest to examine whether the prevalence of an elevated 
systemic inflammatory response was comparable or varied across different ethnic populations 
after controlling for clinical and pathological characteristics.  Also, if different, it would 
suggest that routine reporting of the systemic inflammatory response would be necessary 
alongside TNM-based reporting to allow for comparison of both disease stage and outcomes.  
Indeed there is some evidence that the proportion of patients with elevated prognostic scores 
varies with ethnicity in patients with cancer (20).  However, to our knowledge the basis of 
this observation is not clear since a number of potential confounding clinicopathological 
factors have not been examined.  Many Asian research groups (in particular in Japan) have 
confirmed the prognostic value of systemic inflammation-based prognostic scores.  As such, 
it is of interest to compare, in detail, patients with colorectal cancer from the UK and Japan. 
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Therefore, using two cohorts of patients in which the mGPS has previously been shown to 
hold prognostic value (7, 12), the aim of the present study was to compare systemic 
inflammatory profiles across two distinct populations of patients undergoing resection of 
stage I-III colorectal cancer in the United Kingdom (UK) and Japan.
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Methods 
UK cohort 
Patients from a single surgical unit at Glasgow Royal Infirmary, UK, (GRI) were identified 
from a prospectively collected database of elective and emergency colorectal cancer 
resections.  For the purposes of the present study, consecutive patients who on the basis of 
preoperative staging and intra-operative findings had undergone potentially curative resection 
of TNM stage I-III colorectal adenocarcinoma between January 1997 and May 2013 were 
included.  Patients with inflammatory bowel disease-related cancer, or who received 
neoadjuvant chemoradiotherapy were excluded. 
Patients undergoing elective resection had differential white cell count, serum CRP and 
albumin measured routinely at preoperative assessment within 30 days of surgery, whereas 
patients undergoing emergency resection had values on admission recorded.  Body mass 
index (BMI) was recorded at time of admission, and categorised using World Health 
Organisation classification.  Comorbidity was measured using American Society of 
Anaesthesiologists’ (ASA) grade, which was recorded at time of surgery.  Tumors were 
staged according to the fifth edition of the TNM classification as is current practice in the UK 
(21).  Elastica staining has been used routinely in GRI since 2003, with selected retrospective 
staining performed on a cohort of patients before this date for a previous study (3).  West of 
Scotland Research Ethics Committee approved the study. 
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Japanese cohort 
Patients were identified from a prospectively maintained database of elective and emergency 
colorectal cancer resections performed by a single surgical team in the Department of 
Gastroenterological Surgery, Dokkyo Medical University, Japan (DMU).  For the present 
study, patients who underwent potentially curative resection of TNM stage I-III colorectal 
adenocarcinoma between November 2005 to December 2015 were included.  Exclusion 
criteria were identical to those applied to the GRI cohort, with pre-operative measurement of 
differential white cell count, CRP and albumin performed on day of admission.  Both BMI 
and ASA grade were recorded at time of admission.  Patients were staged according to the 
seventh edition of the TNM classification (22).  Elastica staining was not used routinely for 
detection of venous invasion, and was only used at the discretion of the reporting pathologist.  
The local institutional review board approved the study. 
Systemic inflammatory scores 
The mGPS was calculated for both cohorts as previously described (6).  Patients with 
CRP≤10mg/L were given a score of 0, patients with CRP>10mg/L a score of 1, and patients 
with CRP>10mg/L and albumin<35g/L a score of 2.  On the basis of a previous literature 
review, a NLR>5 was considered elevated (23). 
Statistical analysis 
The relationship between study cohort, mGPS and clinicopathological characteristics was 
examined using the χ2 method for linear trend.  In order to adjust for multiple comparisons, a 
P<0.01 was considered significant.  Univariate binary logistic regression was used to 
examine the relationship between clinicopathological characteristics, including study cohort, 
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and the presence of a systemic inflammatory response (mGPS≥1 or NLR>5), calculating 
odds ratio (OR) and 95% confidence intervals (95% CI).  Clinicopathological factors 
associated with the presence of a systemic inflammatory response that on univariate analysis 
had a P <0.05 were taken into a multivariate model using a backward conditional model to 
identify independently significant factors, with P≤0.05 considered statistically significant.  
All analyses were performed using SPSS version 22.0 for Mac (IBM SPSS, IL, USA).
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Results 
The final study population comprised 1140 patients (581 patients from GRI and 559 patients 
from DMU).  Data on BMI were missing for 175 patients from GRI.  Data on BMI, lymph 
node yield, venous invasion and margin involvement were missing for 4, 2, 6 and 8 patients 
respectively from DMU. 
A comparison of characteristics of the two cohorts is displayed in Table 1.  Patients from GRI 
were more likely to have a high ASA grade and BMI, and present as an emergency 
(P<0.001).  Patients from DMU were more likely to undergo resection for rectal cancer 
(P=0.001).  N stage and lymph node yield did not differ significantly; patients from GRI were 
more likely to have advanced disease as evidenced by T stage, peritoneal and margin 
involvement and TNM stage (due to higher proportion of stage II disease).  Conversely 
patients from DMU were more likely to have evidence of venous invasion and tumour 
perforation.  Patients from GRI were more likely to show evidence of an elevated systemic 
inflammatory response as measured by both mGPS (mGPS1: 41% vs. 16%, P<0.001) and 
NLR (19% vs. 12%, P=0.001). 
Binary logistic regression analysis was subsequently performed to identify host and tumor 
characteristics, including study cohort, associated with the presence of an elevated systemic 
inflammatory response (Table 2).  On univariate analysis, advancing age, ASA grade, 
emergency presentation, T stage, margin involvement, peritoneal involvement and tumor 
perforation were associated with mGPS≥1 (all P<0.01), whereas patients with a rectal 
primary and from DMU were less likely to have an elevated mGPS (both P<0.001).  On 
multivariate analysis, when considering only variables with P≤0.05 on univariate analysis, 
advancing age (OR 1.34, P=0.002), ASA grade (OR 1.25, P=0.046), emergency presentation 
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(OR 3.07, P<0.001), rectal primary (OR 0.57, P=0.001), T stage (OR 1.62, P<0.001), margin 
involvement (OR 2.24, P=0.011), tumor perforation (OR 2.28, P=0.024) and study cohort 
(DMU: OR 0.37, P<0.001) were independently associated with the presence of an elevated 
mGPS. 
When the relationship between host and tumor characteristics associated with the presence of 
an elevated NLR was examined (Table 2), age (OR 1.46, P=0.001), BMI (OR 0.59, 
P<0.001), emergency presentation (OR 3.11, P<0.001), T stage (OR 1.24, P=0.043) and 
study cohort (DMU: OR 0.53, P=0.002) were independently associated with NLR>5. 
To control for the effect of tumor location and emergency presentation on the presence of a 
systemic inflammatory response, binary logistic regression was performed on patients 
undergoing elective resection of stage I-III colon cancer only (Table 3).  On multivariate 
analysis, age (OR 1.51, P<0.001), T stage (OR 1.77, P<0.001), tumor perforation (OR 4.91, 
P=0.005) and study cohort (DMU: OR 0.34, P<0.001) were independently associated with 
the presence of an elevated mGPS.  Age (OR 1.47, P=0.004), T stage (OR 1.45, P=0.009), 
tumor perforation (OR 5.72, P=0.001) and study cohort (DMU: OR 0.57, P=0.013) were 
independently associated with the presence of an elevated NLR. 
Finally, how the presence of an elevated systemic inflammatory response differed across 
different disease stages between the two cohorts was examined (Table 4).  Patients from GRI 
were more likely to exhibit an elevated mGPS when stratified by T stage; although 
statistically significant for patients with T2-4 disease (all P<0.05), this failed to reach 
statistical significance for patients with T1 disease (P=0.184).  When stratified by TNM 
stage, patients from GRI were more likely to exhibit an elevated mGPS.  Although patients 
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from GRI were more likely to have an elevated NLR, this only reached statistical significance 
for patients with T3 disease (P=0.019). 
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Discussion 
In the present study, there were significant differences in both patient and tumor-related 
characteristics of patients undergoing potentially curative resection of stage I-III colorectal 
cancer in two single institutions in the UK and Japan.  Furthermore, systemic inflammatory 
profiles differed in these two patient cohorts, independent of other tumor and host factors.  
Therefore, the results of the present study suggest that the magnitude of the pre-operative 
systemic inflammatory response is dependent, at least in part, on racial and ethnic differences 
in the tumor host response.  Given the adverse effect of the systemic inflammatory response 
on prognosis, these findings add further support to the routine reporting of systemic 
inflammation-based prognostic scores alongside routine TNM- based staging, particularly 
when comparing outcomes globally. 
Patients from GRI and DMU differed with respect to tumor characteristics.  Patients from 
GRI were more likely to undergo resection for tumors with a higher T stage, a tumor 
characteristic which has remained stable across different iterations of TNM staging.  This 
preponderance towards a higher T stage would account for differences in pathological 
characteristics such as the increased rates of peritoneal involvement observed in patients from 
GRI.  However, it was of interest that patients from DMU were more likely to have evidence 
of venous invasion; this difference persisted even when analysis was restricted to patients 
from GRI following the introduction of routine elastica staining (P<0.001).  Indeed, given the 
routine use of elastica staining in GRI but not DMU, it would be expected that rates of 
venous invasion would be higher in the former, contrary to the present results.  However, 
other differences in pathological techniques and reporting may be important; for example, 
sampling technique and thoroughness of pathological assessment (24), or the definition of 
venous invasion as either the presence of extra-mural invasion only or both extra- and intra-
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mural invasion (24, 25).  Nevertheless, it is worth noting that even in the GRI cohort, 
detection of venous invasion was still greater than the minimum audit standard of 30% 
recommended by the Royal College of Pathologists (21).  Further work is required to 
understand the differences in tumor characterisation in the UK and Japan. 
With reference to patient-related characteristics, GRI patients were more likely to be obese, 
have a higher burden of comorbidity and be more likely to present as an emergency.  Such 
factors have previously been identified as poor prognostic factors in patients undergoing 
resection of colorectal cancer; for example, emergency presentation is associated with a two-
fold increased risk of cancer death (26).  Similarly, comorbidity and physiological status are 
independent determinants of survival (27).  Although it would be of interest to examine more 
objective measures of comorbidity, the present results highlight the importance of assessment 
of not only tumor, but also host characteristics when comparing outcomes.   
Nevertheless, even after controlling for clinicopathological characteristics, patients from the 
UK were more likely to exhibit elevated systemic inflammatory responses as measured by 
both mGPS and NLR.  This is consistent with previous studies which have identified lower 
circulating CRP concentrations in healthy individuals of East Asian origin compared to those 
of European descent (17-19, 28).  Similarly, the NLR has been shown to differ with race/ 
ethnicity (29).  It was of interest that increasing T stage was associated with increasing 
prevalence of elevated systemic inflammatory responses in both cohorts.  We have previously 
reported that an elevated mGPS may be observed in 50% of patients with T4 tumors 
compared to only 25% of those with T1 disease (30).  Despite this, across all stages there 
remained a consistently higher proportion of patients from GRI with elevated mGPS.  
Although this failed to reach statistical significance for patient with T1 tumours, this likely 
reflects the small number of patients in this subgroup (n=28 and n=88 for GRI and DMU 
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respectively).  As such, given the relatively small proportion of patients in this subgroup who 
would be expected to be systemically inflamed, the present study was likely underpowered to 
test for statistical significance. 
Although the increased prevalence of an elevated systemic inflammatory response may be 
explained by differences in socioeconomic and lifestyle characteristics, markers of 
inflammation differ widely in individuals of different ethnicity resident in the same 
geographical location, thereby limiting the role of environmental factors and implicating 
other, intrinsic, factors (16, 28).  Circulating CRP levels are partly determined by genetic 
polymorphisms (31).  Several associated single nucleotide polymorphisms (SNPs) have been 
identified (32-34), with a difference in not only their prevalence, but also their subsequent 
effect on CRP concentrations across different ethnic populations (33).  A number of these 
SNPs have been confirmed as potential determinants of CRP concentrations in individuals of 
Asian descent (34), and the differences observed presently may reflect such underlying 
genetic determinants.  However, previous studies have generally considered mean population 
CRP concentrations in the region of 1-5mg/L, rather than >10mg/L as in the present study.  
Furthermore, in a prior study of patients with advanced cancer, no relationship between a 
number of candidate SNPs associated with inflammation and elevated CRP concentrations in 
the context of the cancer cachexia syndrome were identified (35). 
A plausible mechanism that may explain the difference both systemic inflammatory 
responses and tumor characteristics is differing tumor biology.  It is now accepted that 
colorectal cancers encompass varying genetic and molecular entities, and such characteristics 
may dictate many facets of tumor behaviour, including tumor-associated inflammation and 
the presence of lymphovascular invasion (36).  For example, it has been reported rates of 
mismatch repair deficient colorectal cancer are lower in Japan compared to Western countries 
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countries (37).  Moreover, the presence of mismatch repair deficiency has previously been 
associated with the presence of an elevated systemic inflammatory response in patients with 
stage I-III colorectal cancer (38).  Therefore, in-depth studies comparing molecular 
characteristics, and utilising standardised pathological techniques and staging systems, is 
warranted. 
The present study has a number of limitations.  Differences in TNM staging between centres 
may confound the results.  However, N stage was not associated with systemic inflammatory 
response in either cohort.  Furthermore, migration from the 5th to 7th edition would be 
expected to account for an upstaging from node negative to node positive disease in less than 
3% of cases, with little subsequent effect on prognosis (39, 40). The present study did not 
consider tumor molecular characteristics, such as mismatch repair deficiency, however, few 
molecular characteristics, except for mismatch repair status and KRAS/BRAF status have 
translated into routine practice.  Due to limitations in the data collected from both centres it is 
not possible to analyse the data specifically by ethnicity.  However, the population served by 
Glasgow Royal Infirmary, UK, is predominantly Caucasian (41).  Similarly, the population 
served by Dokkyo Medical University, Japan, is predominantly east Asian (42).  Therefore, 
although ethnicity was not specifically controlled for in each centre, it is unlikely that it was a 
major confounder in the present results. 
The results of the present study identify several points for further consideration.  Firstly, the 
difference in systemic inflammatory profiles between geographically distinct populations 
raises issue with respect to the reporting of colorectal cancer outcomes.  Whereas TNM 
staging has been standardised internationally to aid in the recruitment to and reporting of 
clinical trials, similar should occur with respect to the systemic inflammatory response.  
Given the previously reported perceived lack of efficacy of adjuvant chemotherapy in the 
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systemically inflamed patient (7), such measures should be routinely reported to allow 
appropriate interpretation of clinical trial data.  However, whether a universally standardised 
threshold (i.e. CRP>10mg/L), or thresholds based on ethnicity should be employed, remains 
to be investigated.  Indeed, previous studies in East Asia and Japan have reported the 
prognostic value of CRP thresholds of 3, 5 and 7.5mg/L (20).  Although utilising a lower 
threshold would accommodate for the lower proportion of patients in Japan who are 
systemically inflamed, it remains to be determined if prognostic value is comparable to a 
CRP>10mg/l in a Western population.  Finally, routine reporting of the systemic 
inflammatory response may identify patients who could potentially benefit from novel 
treatment strategies targeting the systemic inflammatory response.  For example, nonsteroidal 
anti-inflammatory drugs are associated with improved survival of patients with colorectal 
cancer, potentially through attenuation of tumor-associated inflammation (43). 
In conclusion, using two geographically distinct populations, the results of the present study 
identified differences in the systemic inflammatory responses of patients undergoing 
potentially curative resection of stage I-III colorectal cancer.  Such measures should be 
considered in future studies reporting outcome of patients undergoing resection of primary 
operable colorectal cancer. 
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Table 1. Comparison of clinicopathological characteristics of patients from Glasgow Royal 
Infirmary, United Kingdom, and Dokkyo Medical University, Japan, undergoing potentially 
curative primary resection of stage I-III colorectal cancer 
  GRI cohort  DMU cohort  
Clinicopathological Characteristics (n=581) (%)   (n=559) (%) P 
Age  
<65 
65-74 
>75 
 
185 (32) 
193 (33) 
203 (35) 
  
211 (38) 
156 (28) 
192 (34) 
0.188 
Sex  
Female 
Male 
 
265 (46) 
316 (54) 
 
 
 
209 (37) 
350 (63) 
0.005 
ASA grade  
I 
II 
III 
IV 
 
69 (12) 
245 (42) 
237 (41) 
30 (5) 
  
100 (18) 
390 (69) 
68 (12) 
1 (0) 
<0.001 
BMI (961)  
<18.5 
18.5-24.9 
25.-29.9 
≥30 
 
17 (4) 
155 (38) 
141 (35) 
93 (23) 
  
76 (14) 
356 (64) 
106 (19) 
17 (3) 
<0.001 
Presentation  
Elective 
Emergency 
 
531 (91) 
50 (9) 
  
546 (98) 
13 (2) 
<0.001 
Tumor site  
Colon 
Rectum 
 
425 (73) 
156 (27) 
  
358 (64) 
201 (36) 
0.001 
T stage   
1 
2 
3 
4 
 
28 (5) 
59 (10) 
322 (55) 
172 (30) 
  
88 (16) 
70 (12) 
308 (55) 
93 (17) 
<0.001 
N stage  
0 
1 
2 
 
358 (62) 
166 (29) 
57 (10) 
  
343 (62) 
157 (28) 
58 (10) 
0.854 
TNM stage  
I 
II 
III 
 
72 (12) 
286 (49) 
223 (38) 
  
140 (25) 
202 (36) 
217 (39) 
0.005 
Venous invasion (1134)  
No 
Yes 
 
292 (50) 
289 (50) 
  
153 (28) 
400 (72) 
<0.001 
Less than 12 lymph nodes retrieved (1138)  
No 
Yes 
 
414 (71) 
167 (29) 
  
400 (72) 
157 (28) 
0.835 
Margin involvement (1132)  
No 
Yes 
 
541 (93) 
40 (7) 
  
532 (97) 
19 (3) 
0.009 
Peritoneal involvement  
No 
Yes 
 
429 (74) 
152 (26) 
  
530 (95) 
29 (5) 
<0.001 
Tumor perforation  
No 
Yes 
 
563 (97) 
18 (3) 
  
523 (94) 
36 (6) 
0.008 
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mGPS  
0 
1 
2 
 
345 (59) 
141 (24) 
95 (17) 
  
469 (84) 
29 (5) 
61 (11) 
<0.001 
NLR  
≤5 
>5 
 
469 (81) 
112 (19) 
  
493 (88) 
66 (12) 
0.001 
(n) given when incomplete data available. P-value given for χ2 method for linear trend 
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Table 2. The relationship between study cohort, host and tumor characteristics and the 
presence of an elevated systemic inflammatory response in patients undergoing resection of 
stage I-III colorectal cancer 
  Univariate OR (95% 
CI) 
P  Multivariate OR (95% 
CI) 
P 
Modified Glasgow Prognostic Score (0 vs. ≥1) 
Age (<65/ 65-74/ >74)  1.43 (1.22-1.68) <0.001  1.34 (1.12-1.61) 0.002 
Sex (female/ male)  0.79 (0.61-1.02) 0.074  - - 
ASA grade (I/ II/ III/ IV)  1.94 (1.60-2.35) <0.001  1.25 (1.00-1.57) 0.046 
BMI (<18.5/ 18.5-24.9/ 25.-29.9/ 
≥30) 
 1.05 (0.88-1.25) 0.608  - - 
Presentation (elective/ 
emergency) 
 7.71 (4.34-13.66) <0.001  3.07 (1.64-5.75) <0.001 
Tumor site (colon/ rectum)  0.46 (0.34-0.62) <0.001  0.57 (0.41-0.80) 0.001 
T stage (1/ 2/ 3/ 4)  2.17 (1.80-2.62) <0.001  1.62 (1.33-1.98) <0.001 
N stage (0/ 1/ 2)  1.01 (0.83-1.22) 0.944  - - 
Less than 12 nodes (no/ yes)  0.97 (0.73-1.29) 0.824  - - 
Venous invasion (absent/ 
present) 
 0.83 (0.64-1.08) 0.160  - - 
Margin involvement (absent/ 
present)  
 3.67 (2.15-6.26) <0.001  2.24 (1.21-4.16) 0.011 
Peritoneal involvement (absent/ 
present) 
 3.68 (2.65-5.11) <0.001  - 0.908 
Tumor perforation (absent/ 
present) 
 2.43 (1.40-4.22) 0.002  2.28 (1.11-4.67) 0.024 
Hospital (GRI/ DMU)  0.28 (0.21-0.37) <0.001  0.37 (0.27-0.50) <0.001 
Neutrophil: lymphocyte ratio (≤5 vs. >5) 
Age (<65/ 65-74/ >74)  1.56 (1.28-1.90) <0.001  1.46 (1.16-1.83) 0.001 
Sex (female/ male)  0.97 (0.70-1.35) 0.870  - - 
ASA grade (I/ II/ III/ IV)  1.58 (1.26-1.98) <0.001  - 0.239 
BMI (<18.5/ 18.5-24.9/ 25.-29.9/ 
≥30) 
 0.66 (0.52-0.84) 0.001  0.59 (0.46-0.77) <0.001 
Presentation (elective/ 
emergency) 
 4.94 (2.92-8.37) <0.001  3.11 (1.42-6.80) <0.001 
Tumor site (colon/ rectum)  0.61 (0.42-0.89) 0.010  - 0.414 
T stage (1/ 2/ 3/ 4)  1.76 (1.41-2.19) <0.001  1.29 (1.01-1.65) 0.043 
N stage (0/ 1/ 2)  1.15 (0.91-1.44) 0.245  - - 
Less than 12 nodes (no/ yes)  1.31 (0.93-1.85) 0.120  - - 
Venous invasion (absent/ 
present) 
 0.87 (0.63-1.21) 0.407  - - 
Margin involvement (absent/ 
present)  
 2.31 (1.28-4.16) 0.005  - 0.126 
Peritoneal involvement (absent/ 
present) 
 2.39 (1.64-3.48) <0.001  - 0.889 
Tumor perforation (absent/ 
present) 
 2.89 (1.60-5.22) <0.001  - 0.212 
Hospital (GRI/ DMU)  0.56 (0.40-0.78) 0.001  0.53 (0.35-0.79) 0.002 
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Table 3. The relationship between study cohort, host and tumor characteristics and the 
presence of an elevated systemic inflammatory response in patients undergoing elective 
resection of stage I-III colon cancer. 
  Univariate OR (95% 
CI) 
P  Multivariate OR (95% 
CI) 
P 
Modified Glasgow Prognostic Score (0 vs. ≥1) 
Age (<65/ 65-74/ >74)  1.44 (1.19-1.75) <0.001  1.51 (1.22-1.86) <0.001 
Sex (female/ male)  0.88 (0.64-1.21) 0.427  - - 
ASA grade (I/ II/ III/ IV)  1.77 (1.40-2.25) <0.001  - 0.101 
BMI (<18.5/ 18.5-24.9/ 25.-29.9/ 
≥30) 
 1.00 (0.80-1.24) 0.986  - - 
T stage (1/ 2/ 3/ 4)  2.03 (1.62-2.53) <0.001  1.77 (1.40-2.24) <0.001 
N stage (0/ 1/ 2)  0.90 (0.70-1.16) 0.427  - - 
Less than 12 nodes (no/ yes)  0.99 (0.69-1.40) 0.941  - - 
Venous invasion (absent/ 
present) 
 0.91 (0.66-1.25) 0.543  - - 
Margin involvement (absent/ 
present)  
 4.41 (1.92-10.14) <0.001  - 0.121 
Peritoneal involvement (absent/ 
present) 
 2.98 (2.00-4.46) <0.001  - 0.841 
Tumor perforation (absent/ 
present) 
 4.90 (1.82-13.24) 0.002  4.91 (1.62-14.90) 0.005 
Hospital (GRI/ DMU)  0.31 (0.22-0.43) <0.001  0.34 (0.23-0.48) <0.001 
Neutrophil: lymphocyte ratio (≤5 vs. >5) 
Age (<65/ 65-74/ >74)  1.42 (1.11-1.83) 0.006  1.47 (1.13-1.90) 0.004 
Sex (female/ male)  1.14 (0.76-1.71) 0.537  - - 
ASA grade (I/ II/ III/ IV)  1.54 (1.15-2.07) 0.004  - 0.206 
BMI (<18.5/ 18.5-24.9/ 25.-29.9/ 
≥30) 
 0.76 (0.57-1.02) 0.066  - - 
T stage (1/ 2/ 3/ 4)  1.66 (1.27-2.18) <0.001  1.45 (1.10-1.91) 0.009 
N stage (0/ 1/ 2)  0.96 (0.70-1.32) 0.806  - - 
Less than 12 nodes (no/ yes)  1.31 (0.85-2.02) 0.220  - - 
Venous invasion (absent/ 
present) 
 0.81 (0.54-1.23) 0.324  - - 
Margin involvement (absent/ 
present)  
 3.31 (1.43-7.71) 0.005  - 0.290 
Peritoneal involvement (absent/ 
present) 
 2.31 (1.44-3.70) 0.001  - 0.523 
Tumor perforation (absent/ 
present) 
 5.97 (2.31-15.40) <0.001  5.72 (2.08-15.73) 0.001 
Hospital (GRI/ DMU)  0.52 (0.34-0.80) 0.003  0.57 (0.37-0.89) 0.013 
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Table 4.  Comparison of the prevalence of an elevated systemic inflammatory response in 
patients undergoing potentially curative, elective resection of colon cancer in Glasgow Royal 
Infirmary and Dokkyo Medical University, stratified by disease stage. 
 T stage  TNM stage 
 1 2 3 4  I II III 
 Percentage of patients with mGPS≥1 
GRI 
DMU 
15.8% 
6.2% 
20.0% 
3.2% 
42.2% 
19.8% 
50.5% 
30.2% 
 18.4% 
5.7% 
49.0% 
27.9% 
38.2% 
15.4% 
P 0.184 0.039 <0.001 0.010  0.021 <0.001 <0.001 
 Percentage of patients with NLR>5 
GRI 
DMU 
10.5% 
4.6% 
8.6% 
12.9% 
18.5% 
10.2% 
25.2% 
19.0% 
 8.2% 
6.9% 
22.4% 
14.0% 
18.3% 
10.8% 
P 0.341 0.571 0.019 0.353  0.787 0.057 0.084 
Data displayed as percentage of patients in each group with elevated systemic inflammatory 
response as measured by mGPS and NLR 
 
 
 
 
